



doseology

Doseology Announces Effective Date for Share Consolidation

Kelowna, British Columbia, February 14, 2024 – **Doseology Sciences Inc.** (CSE: **MOOD**) (OTCQB: **DOSEF**) (FSE: **VU7**) (“Doseology” or the “Company”), Doseology, an innovator in functional mushroom wellness products, announces, further to its news release of February 8, 2024, that the consolidation of its issued and outstanding common shares on the basis of ten (10) existing common shares for one (1) new common share of the Company will take effect at market open on Friday, February 16, 2024 (the “**Consolidation**”). At this time, the Company’s common shares will commence trading on the Canadian Securities Exchange on a post-Consolidation basis.

On a pre-Consolidation basis, the Company has 44,005,250 common shares issued and outstanding, and, following the Consolidation, the Company expects to have 4,400,515 post-Consolidation shares issued and outstanding, subject to rounding.

No fractional shares will be issued pursuant to the Consolidation. Any fractional shares will be rounded down to the nearest whole number of common shares. No cash consideration will be paid in respect of fractional shares.

The CUSIP number for its post-Consolidation common shares will be 258484203 and ISIN will be CA2584842033.

About Doseology Sciences Inc. (CSE: **MOOD**) (OTCQB: **DOSEF**) (FSE: **VU7**)

Doseology specializes in premium functional mushroom and adaptogenic herbal supplements that are stacked for targeted results. Our products are science-backed and health expert-formulated, addressing today's top wellness needs. With 100% mushroom fruiting bodies for maximum purity and potency, we leave no room for compromise. Our liquid format ensures faster absorption for an efficient wellness experience. At Doseology, we're committed to optimizing well-being through the power of nature, offering investors an opportunity to join our journey toward optimal wellness.

On behalf of the Board of Directors,
Shawn Balaghi
Interim Chief Executive Officer
Doseology Sciences Inc.

For further information contact:

Investor Relations: investor@doseology.com

Sales Inquiries: hello@doseology.com

Telephone: +1 825-800-0115

Website: doseology.com

Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

The CSE does not accept responsibility for the adequacy or accuracy of this release.